(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 June 2005 (02.06.2005)

PCT

(10) International Publication Number
WO 2005/049578 A1

(51) International Patent Classification[7]: C07D 231/14, 409/10, 405/10, 401/10, 231/12, A61K 31/415, A61P 3/00

(21) International Application Number:
PCT/EP2004/012965

(22) International Filing Date:
15 November 2004 (15.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0326747.3 17 November 2003 (17.11.2003) GB
0329462.6 19 December 2003 (19.12.2003) GB

(71) Applicant *(for all designated States except US)*: SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, P.O. Box 7929, Philadelphia, Pennsylvania 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: FAUCHER, Nicolas Eric [FR/FR]; GlaxoSmithKline, Centre de Recherches, ZA de Courtaboeuf, 25 Avenue du Quebec, F-91940 Les Ulis (FR). MARTRES, Paul [FR/FR]; GlaxoSmithKline, Centre de Recherches, ZA de Courtaboeuf, 25 Avenue du Quebec, F-91940 Les Ulis (FR).

(74) Agent: LEAROYD, Stephanie, Anne; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED PYRAZOLES AS PPAR AGONISTS



(I)

(57) Abstract: A compound of formula (I) and pharmaceutically acceptable salts, solvates and hydrolysable esters thereof (I) wherein: p is O or 1; q is O or 1; R^1 and R^2 are independently H or C_{1-3} alkyl; R^3 and R^4 are independently H, C_{1-6} alkyl, $-OC_{1-6}$ alkyl, halogen, OH, C_{2-6} alkenyl or CF_3; R^5 is H, C_{1-6} alkyl (optionally substituted by one or more halogens, -COphenyl, OC_{1-6} alkyl, phenyl morpholino or C_{2-6} alkenyl. R^6 is C_{1-6} alkyl, halogen, $-OCH_2$ phenyl, phenyl (optionally substituted by C_{1-3} alkiyl), morpholino, pyrrolidino, piperidino, thiophenyl, furanyl pyridinyl or $-OC_{2-6}$ alkenyl. These compounds activate the alpha and gamma subtypes fo the hppar receptor and are useful e.g. in the treatment of diabetes, dyslipidemia or syndrome X.

WO 2005/049578 A1